<p><em>经验丰富的硅谷创始人和高管带来了通过全球商业化和并购扩展先进平台的成功经验</em></p>
<p>, /PRNewswire/ -- Arkstone Medical Solutions 是一家通过 “专家参与” 的机器学习（ML）和人工智能（AI）来转变临床决策支持（CDS）的生物技术公司，今天宣布任命 <strong>Ian Campbell</strong> 为首席执行官。Campbell 在公司加速产品创新、扩展全球足迹并推进其通过精准指导的临床决策支持来应对抗微生物耐药性和其他重大医疗问题的使命之际加入 Arkstone，此前公司获得了 ARCHIMED 的 MED Rise 基金的早期融资。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Arkstone 首席执行官 Ian Campbell</p>
<p>&#34;Ian 是一位经过验证的领导者，具备扩展技术复杂平台的罕见能力，并成功引导组织经历转型增长和收购，&#34;Arkstone 首席科学官 <strong>Ari Frenkel, MD, MPH</strong> 表示。&#34;他在建立世界级团队、推动产品创新和高层执行方面的经验将在 Arkstone 进入下一个阶段时发挥重要作用。&#34;</p>
<p>Ian Campbell 拥有超过二十年的领导经验，涵盖企业软件、先进工程平台、产品开发以及建立高增长技术组织。最近，他担任云原生仿真公司 OnScale 的首席执行官，该公司的技术于 2022 年被 Ansys 收购，以扩展 Ansys 的云产品组合，并实现对先进仿真工具的完全基于网络、设备无关的访问。</p>
<p>在 OnScale 之前，Ian Campbell 是 NextInput 的创始首席执行官，他招募了一支顶尖的管理和工程团队，领导公司 ForceTouch 解决方案的所有研发和产品开发，并在亚洲获得了公司的首个主要智能手机 OEM 设计胜利。NextInput 于 2021 年被 Qorvo 收购，进一步证明了 Campbell 在将差异化技术平台扩展至成功退出方面的记录。</p>
<p>&#34;我很荣幸在如此重要的转折点加入 Arkstone，&#34;Campbell 表示。&#34;Arkstone 在关键时刻提供可操作的、AI 驱动的临床指导的能力既强大又及时。我期待与这个杰出的团队合作，扩展平台，加深其临床影响，并帮助解决全球医疗保健中最紧迫的挑战之一。&#34;</p>
<p>Campbell 拥有乔治亚理工学院 Scheller 商学院的 MBA，专注于战略、运营、私募股权和创业，以及航空航天工程硕士和机械工程学士学位。他在构建可扩展的、基于云和 AI 的 SaaS 平台以及领导多学科技术团队方面的背景将帮助 Arkstone 继续扩展其技术和市场影响力。</p>
<p>在 Campbell 的领导下，Arkstone 将继续推进其旗舰产品 OneChoice®报告，该报告在实验室结果接收时提供患者特定的、AI 驱动的临床建议——使临床医生能够负责任地开处方（Prescribe Responsibly®），并帮助医疗系统应对抗微生物耐药性。</p>
<p><strong>关于 Arkstone Medical Solutions</strong></p>
<p>Arkstone 是一家生物技术公司，推出了全球首个 “专家参与”（EITL）机器学习和人工智能驱动的临床决策平台，以协助临床医生在感染疾病等领域进行关键治疗。</p>
<p><strong>媒体联系人：</strong> Arkstone Medical Solutions</p>
<p>[email protected] | www.arkstone.ai</p>
<p>1-833-933-ARK(275)-3</p>
<p>来源 Arkstone</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA4Jk5ld3NJdGVtSWQ9UEg1ODc4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDgwODMxUFJfTkVXU19VU1BSX19fX19QSDU4Nzg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA4Jk5ld3NJdGVtSWQ9UEg1ODc4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDgwODMxUFJfTkVXU19VU1BSX19fX19QSDU4Nzg5"/></p>

<p>Arkstone Medical Solutions 任命 Ian Campbell 为首席执行官，以引领公司进入下一个增长和创新阶段。Campbell 是一位经验丰富的高管，拥有超过二十年的先进技术平台扩展经验，他将专注于产品创新和扩大 Arkstone 的全球影响力。他的领导目标是提升公司基于人工智能的临床决策支持解决方案，特别是在应对抗微生物耐药性方面。Campbell 拥有 MBA 学位和高级工程学位，为 Arkstone 带来了强大的云计算和人工智能平台背景</p>

<p><em>Seasoned Silicon Valley founder and executive brings proven experience scaling advanced platforms through global commercialization and M&amp;A</em></p>
<div class="lb-trans"><p><em>经验丰富的硅谷创始人和高管带来了通过全球商业化和并购扩展先进平台的成功经验</em></p>
</div><p>, /PRNewswire/ -- Arkstone Medical Solutions, a biotechnology company transforming Clinical Decision Support (CDS) through &#34;Expert-in-the-Loop&#34; machine learning (ML) and artificial intelligence (AI), today announced the appointment of <strong>Ian Campbell</strong> as Chief Executive Officer. Campbell joins Arkstone at a pivotal moment as the company accelerates product innovation, expands its global footprint, and advances its mission to combat antimicrobial resistance and other major healthcare issues with precision-guided clinical decision support, after the company's recent early-stage funding from ARCHIMED's MED Rise fund.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Arkstone Medical Solutions 是一家通过 “专家参与” 的机器学习（ML）和人工智能（AI）来转变临床决策支持（CDS）的生物技术公司，今天宣布任命 <strong>Ian Campbell</strong> 为首席执行官。Campbell 在公司加速产品创新、扩展全球足迹并推进其通过精准指导的临床决策支持来应对抗微生物耐药性和其他重大医疗问题的使命之际加入 Arkstone，此前公司获得了 ARCHIMED 的 MED Rise 基金的早期融资。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Ian Campbell, Chief Executive Officer of Arkstone</p>
<div class="lb-trans"><p>Arkstone 首席执行官 Ian Campbell</p>
</div><p>&#34;Ian is a proven leader with a rare ability to scale technically complex platforms and successfully guide organizations through transformational growth and acquisition,&#34; said <strong>Ari Frenkel, MD, MPH, Chief Science Officer of Arkstone</strong>. &#34;His experience building world-class teams, driving product innovation, and executing at the highest levels will be instrumental as Arkstone enters its next phase.&#34;</p>
<div class="lb-trans"><p>&#34;Ian 是一位经过验证的领导者，具备扩展技术复杂平台的罕见能力，并成功引导组织经历转型增长和收购，&#34;Arkstone 首席科学官 <strong>Ari Frenkel, MD, MPH</strong> 表示。&#34;他在建立世界级团队、推动产品创新和高层执行方面的经验将在 Arkstone 进入下一个阶段时发挥重要作用。&#34;</p>
</div><p>Ian Campbell brings more than two decades of leadership experience spanning enterprise software, advanced engineering platforms, product development, and building high-growth technology organizations. Most recently, he served as Chief Executive Officer of OnScale, a cloud-native simulation company whose technology was acquired by Ansys in 2022 to expand Ansys' cloud portfolio and enable fully web-based, device-independent access to advanced simulation tools.</p>
<div class="lb-trans"><p>Ian Campbell 拥有超过二十年的领导经验，涵盖企业软件、先进工程平台、产品开发以及建立高增长技术组织。最近，他担任云原生仿真公司 OnScale 的首席执行官，该公司的技术于 2022 年被 Ansys 收购，以扩展 Ansys 的云产品组合，并实现对先进仿真工具的完全基于网络、设备无关的访问。</p>
</div><p>Prior to OnScale, Ian Campbell was the founding CEO at NextInput, where he recruited a top-tier management and engineering team, led all R&amp;D and product development for the company's ForceTouch solutions, and secured the company's first major smartphone OEM design wins in Asia. NextInput was acquired by Qorvo in 2021, further underscoring Campbell's track record of scaling differentiated technology platforms to successful exits.</p>
<div class="lb-trans"><p>在 OnScale 之前，Ian Campbell 是 NextInput 的创始首席执行官，他招募了一支顶尖的管理和工程团队，领导公司 ForceTouch 解决方案的所有研发和产品开发，并在亚洲获得了公司的首个主要智能手机 OEM 设计胜利。NextInput 于 2021 年被 Qorvo 收购，进一步证明了 Campbell 在将差异化技术平台扩展至成功退出方面的记录。</p>
</div><p>&#34;I'm honored to join Arkstone at such an important inflection point,&#34; said Campbell. &#34;Arkstone's ability to deliver actionable, AI-driven clinical guidance at the moment it matters most is both powerful and timely. I'm excited to work with this exceptional team to scale the platform, deepen its clinical impact, and help address one of the most urgent challenges in global healthcare.&#34;</p>
<div class="lb-trans"><p>&#34;我很荣幸在如此重要的转折点加入 Arkstone，&#34;Campbell 表示。&#34;Arkstone 在关键时刻提供可操作的、AI 驱动的临床指导的能力既强大又及时。我期待与这个杰出的团队合作，扩展平台，加深其临床影响，并帮助解决全球医疗保健中最紧迫的挑战之一。&#34;</p>
</div><p>Campbell holds an MBA from the Georgia Tech Scheller College of Business, with a focus on strategy, operations, private equity, and entrepreneurship, as well as a Master of Science in Aerospace Engineering and a Bachelor of Science in Mechanical Engineering. His background in building scalable, cloud and AI-enabled SaaS platforms and leading multidisciplinary technical teams will help Arkstone to continue expanding its technology and market presence.</p>
<div class="lb-trans"><p>Campbell 拥有乔治亚理工学院 Scheller 商学院的 MBA，专注于战略、运营、私募股权和创业，以及航空航天工程硕士和机械工程学士学位。他在构建可扩展的、基于云和 AI 的 SaaS 平台以及领导多学科技术团队方面的背景将帮助 Arkstone 继续扩展其技术和市场影响力。</p>
</div><p>Under Campbell's leadership, Arkstone will continue to advance its flagship OneChoice® Report, which delivers patient-specific, AI-powered clinical recommendations at the moment laboratory results are received—empowering clinicians to Prescribe Responsibly® and helping health systems combat antimicrobial resistance.</p>
<div class="lb-trans"><p>在 Campbell 的领导下，Arkstone 将继续推进其旗舰产品 OneChoice®报告，该报告在实验室结果接收时提供患者特定的、AI 驱动的临床建议——使临床医生能够负责任地开处方（Prescribe Responsibly®），并帮助医疗系统应对抗微生物耐药性。</p>
</div><p><strong>About Arkstone Medical Solutions</strong></p>
<div class="lb-trans"><p><strong>关于 Arkstone Medical Solutions</strong></p>
</div><p>Arkstone is a biotechnology company that has launched the world's first &#34;Expert-in-the-Loop&#34; (EITL) ML- and AI-powered clinical decision platform to assist clinicians with critical treatment in areas like infectious disease.</p>
<div class="lb-trans"><p>Arkstone 是一家生物技术公司，推出了全球首个 “专家参与”（EITL）机器学习和人工智能驱动的临床决策平台，以协助临床医生在感染疾病等领域进行关键治疗。</p>
</div><p><strong>Media Contact:</strong> Arkstone Medical Solutions</p>
<div class="lb-trans"><p><strong>媒体联系人：</strong> Arkstone Medical Solutions</p>
</div><p>[email protected] | www.arkstone.ai</p>
<div class="lb-trans"><p>[email protected] | www.arkstone.ai</p>
</div><p>1-833-933-ARK(275)-3</p>
<div class="lb-trans"><p>1-833-933-ARK(275)-3</p>
</div><p>SOURCE Arkstone</p>
<div class="lb-trans"><p>来源 Arkstone</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA4Jk5ld3NJdGVtSWQ9UEg1ODc4OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDgwODMxUFJfTkVXU19VU1BSX19fX19QSDU4Nzg5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH58789&amp;Transmission_Id=202601080831PR_NEWS_USPR_____PH58789&amp;DateId=20260108"/></p>

Arkstone 任命 Ian Campbell 为首席执行官，领导公司进入下一阶段的增长与创新